AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 176-191
The fat-burning fragment of growth hormone. Without the growth hormone side effects.
Educational content only. Not medical advice. This compound may be regulated in your jurisdiction. Consult a healthcare professional.
01 What is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone (specifically amino acids 176-191). It was developed to isolate the fat-burning properties of GH while eliminating the muscle growth, blood sugar, and other effects. The result: a peptide that specifically targets fat metabolism. Originally developed by Monash University in Australia and licensed to Metabolic Pharmaceuticals, it went through Phase II clinical trials for obesity. While it didn't get FDA approval as a drug, it was approved by the FDA as a food ingredient (GRAS status) in 2020 — a unusual pathway that reflects its strong safety profile.
02 How Does It Work?
AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) by mimicking the way natural growth hormone regulates fat metabolism. Unlike full GH, it doesn't affect blood sugar levels or promote muscle/bone growth. It specifically targets adipose (fat) tissue without the systemic effects of growth hormone — no enlarged organs, no insulin resistance, no water retention.
03 What Does The Research Say?
Moderate evidence. Some human data, mostly animal studies.
Phase II clinical trials showed statistically significant fat loss compared to placebo, with an excellent safety profile. The FDA GRAS (Generally Recognized As Safe) designation in 2020 further supports its safety. However, it never achieved Phase III approval as a weight loss drug. The weight loss was modest compared to newer GLP-1 agonists like Semaglutide. In the post-Ozempic world, AOD-9604's value proposition is its targeted fat loss without systemic hormonal effects.
04 Reported Dosages
Research literature dosages only. NOT medical recommendations. Always consult a healthcare professional.
Clinical trial dose: 1mg daily via subcutaneous injection. Community reports: 250mcg-500mcg daily, typically before fasting or morning cardio. FDA GRAS for oral use as food ingredient at lower doses. These are research dosages, not medical recommendations.
05 Side Effects & Risks
Excellent safety profile in clinical trials. Minimal reported side effects: occasional injection site irritation, mild headache. No effect on blood glucose, IGF-1, or cortisol levels — which is the whole point.
06 Legal Status
Not approved as medication. Available as research chemical.
Not FDA-approved as drug. FDA GRAS as food ingredient. Available as research chemical.
Not approved.
Developed in Australia. TGA Schedule 4 (prescription). Banned by WADA.
Goal Guides for AOD-9604
Explore how AOD-9604 may support specific health goals:
Browse all goal guides →